Abstract
The development of therapeutic monoclonal antibodies (mAbs) has revolutionized the treatment of cancer along the last ten years. The best examples of their therapeutic efficacies have been obtained with rituximab for the treatment of CD20+ B-cell Non-Hodgkin Lymphoma (B-NHL), and several others antibodies with optimized bioactivities are now being developed for the treatment of various malignant hemopathies. We review here the main drugs developed in this field, and present some emerging concepts able to improve the bioactivities of the next generation of therapeutic mAbs.
Keywords: Cancer, lymphoma, therapy, antibodies, phosphoantigens
Current Drug Targets
Title: Emerging Concepts for the Treatment of Hematological Malignancies with Therapeutic Monoclonal Antibodies
Volume: 11 Issue: 7
Author(s): Aude-Helene Capietto, Samarh Keirallah, Emilie Gross, Nicolas Dauguet, Emilie Laprevotte, Christine Jean, Julie Gertner-Dardenne, Christine Bezombes, Anne Quillet-Mary, Mary Poupot, Loic Ysebaert, Guy Laurent and Jean-Jacques Fournie
Affiliation:
Keywords: Cancer, lymphoma, therapy, antibodies, phosphoantigens
Abstract: The development of therapeutic monoclonal antibodies (mAbs) has revolutionized the treatment of cancer along the last ten years. The best examples of their therapeutic efficacies have been obtained with rituximab for the treatment of CD20+ B-cell Non-Hodgkin Lymphoma (B-NHL), and several others antibodies with optimized bioactivities are now being developed for the treatment of various malignant hemopathies. We review here the main drugs developed in this field, and present some emerging concepts able to improve the bioactivities of the next generation of therapeutic mAbs.
Export Options
About this article
Cite this article as:
Capietto Aude-Helene, Keirallah Samarh, Gross Emilie, Dauguet Nicolas, Laprevotte Emilie, Jean Christine, Gertner-Dardenne Julie, Bezombes Christine, Quillet-Mary Anne, Poupot Mary, Ysebaert Loic, Laurent Guy and Fournie Jean-Jacques, Emerging Concepts for the Treatment of Hematological Malignancies with Therapeutic Monoclonal Antibodies, Current Drug Targets 2010; 11 (7) . https://dx.doi.org/10.2174/138945010791320845
DOI https://dx.doi.org/10.2174/138945010791320845 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Synthetic Lethal Interactions in Cancer Therapy
Current Cancer Drug Targets Gene Therapy Approaches for Cartilage Injury and Osteoarthritis
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Design of Peptide-Based Vaccines for Cancer
Current Medicinal Chemistry NAD<sup>+</sup>-Dependent Enzymes at the Endoplasmic Reticulum
Current Topics in Medicinal Chemistry Sequence and Structural Elements in the Mechanism of Function of Rhodopsin-Like Family of G Protein-Coupled-Receptors
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery High-level Soluble Expression, Purification, and Functional Characterization of the Recombinant Human Leukemia Inhibitory Factor: A Potential General Strategy for the Recombinant Expression of Cytokines Consisting of Four α-Helices in a Bundle
Protein & Peptide Letters Nucleoside Phosphorylases
Current Organic Chemistry Signal Transduction Pathways of Taxanes-Induced Apoptosis
Current Medicinal Chemistry - Anti-Cancer Agents Microenvironmental Regulation of Cancer Stem Cell Phenotypes
Current Stem Cell Research & Therapy Peptides for Diagnosis and Treatment of Colorectal Cancer
Current Medicinal Chemistry Design and Synthesis of Some Newer Pyrimidine Hydroxamates as Histone Deacetylase Inhibitors
Current Enzyme Inhibition Normobaric Hyperoxia Preconditioning Induces Changes in the Brain Lipidome
Current Neurovascular Research Carfilzomib: A Tale of a Heartbreaking Moment: Case Report and Concise Review of the Literature
Cardiovascular & Hematological Disorders-Drug Targets MicroRNA Therapeutics: The Emerging Anticancer Strategies
Recent Patents on Anti-Cancer Drug Discovery Iron Chelating Strategies in Systemic Metal Overload, Neurodegeneration and Cancer
Current Medicinal Chemistry Carcinogenicity and Chronic Rodent Toxicity of the Selective Progesterone Receptor Modulator Ulipristal Acetate
Current Drug Safety Recent Patents in Toll-like Receptor Pathways and Relevance to Cancer
Recent Patents on Anti-Cancer Drug Discovery The Return of the INGs, Histone Mark Sensors and Phospholipid Signaling Effectors
Current Drug Targets Oxidative Stress, Redox Signaling and Cancer Chemoresistance: Putting Together the Pieces of the Puzzle
Current Medicinal Chemistry T Cell Suicide Gene Therapy to Aid Haematopoietic Stem Cell Transplantation
Current Gene Therapy